Bioneer Unveils BioSPHEER™: A 3D Cancer Model Revolutionizing Solid Tumor Drug Discovery

July 5, 2026

Bioneer デンマーク

Overview

Bioneer has launched BioSPHEER™, an innovative in vitro 3D cancer platform designed to significantly enhance drug efficacy prediction for solid tumors. This platform generates high-fidelity tumor models by assembling fibroblast and cancer cell spheroids, accurately recapitulating the complex tumor microenvironment and cellular heterogeneity. BioSPHEER™ offers advanced insights for drug screening, including sophisticated immunotherapies, promising to accelerate drug development and reduce clinical attrition rates.

In Depth

Background

For decades, oncology drug development has grappled with the inherent limitations of conventional in vitro and in vivo models. Two-dimensional (2D) cell cultures, while foundational, vastly oversimplify the intricate cellular architecture and microenvironmental cues crucial for tumor progression and drug response. Conversely, animal models, though biologically complex, often suffer from species-specific physiological differences and ethical considerations, leading to suboptimal translatability of preclinical findings to human clinical outcomes. The emergence of three-dimensional (3D) cell culture technologies, particularly organoids and spheroids, is now addressing these critical gaps by providing more physiologically relevant in vitro systems. Bioneer’s BioSPHEER™ platform represents a significant advancement in this progression, offering a next-generation approach to cancer modeling.

Key Findings

Bioneer has introduced BioSPHEER™, a state-of-the-art in vitro 3D cancer platform engineered to substantially improve the predictive accuracy of drug efficacy against solid tumors. This innovative system constructs bespoke tumor models using spheroids meticulously composed of fibroblasts and cancer cells, thereby accurately simulating the intricate complexity and cellular diversity characteristic of the tumor microenvironment (TME). These models offer insights superior to those gleaned from conventional 2D cultures and traditional animal models.

Customizable Tumor Models: BioSPHEER™ provides the flexibility to create tailored tumor models by combining specific types and ratios of fibroblast and cancer cell spheroids. This allows researchers to precisely mimic the heterogeneous cellular composition of various tumors, enabling a more accurate assessment of differential responses to therapeutic agents.
Advanced TME Recapitulation: The platform’s sophisticated 3D spheroid architecture effectively recapitulates critical aspects of the tumor microenvironment, including angiogenesis, immune cell infiltration, and complex extracellular matrix interactions. These elements are fundamental to cancer progression and drug resistance. By fostering cellular behavior that closely resembles in vivo conditions, BioSPHEER™ facilitates a more precise evaluation of drug penetration, metabolism, and pharmacodynamic effects within a physiologically relevant context.
Enhanced Predictive Insights: BioSPHEER™ offers invaluable predictive insights into crucial cell-to-cell interactions and mechanisms of drug resistance—factors frequently overlooked or inadequately represented in conventional 2D cultures. This capability is instrumental in accelerating the identification of promising drug candidates early in the discovery process, thereby mitigating the high attrition rates typically associated with later-stage clinical development.
Optimized for Immunotherapy Evaluation: Particularly for advanced immune cell therapies such as CAR T cells, BioSPHEER™ provides a more realistic 3D environment to assess the intricate interactions between immune cells and tumor cells. This significantly improves the predictive accuracy of therapeutic outcomes for these complex and rapidly evolving treatments.

The development of high-fidelity 3D cancer models like BioSPHEER™ establishes a more reliable and biologically relevant platform for comprehensive drug screening, toxicology testing, and the advancement of personalized medicine strategies. This is projected to markedly enhance the efficiency of drug development, reduce associated timelines and costs, and ultimately expedite the creation of safer and more effective therapies for patients. Looking ahead, the anticipated integration of BioSPHEER™ with artificial intelligence is expected to enable even more sophisticated drug efficacy prediction and personalized treatment strategy formulation, further transforming the landscape of oncology research and clinical practice.

Source: https://bioneer.dk/our-services/biospheer-3d-cancer-model/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.